Eli Lilly And Co vs Moderna, Inc. — how do they compare? Eli Lilly And Co trades at $1,161 (market cap $1.02T), while Moderna, Inc. trades at $60.13 (market cap $23.60B). The key difference: Eli Lilly And Co is far larger — about 43.2× Moderna, Inc.'s market cap, and Eli Lilly And Co pays a 0.6% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| LLY | MRNA | |
|---|---|---|
Market Cap | $1.02T | $23.60B |
Sector | Health | Health |
52-Week High | $1.24K | $81.80 |
52-Week Low | $625.65 | $22.36 |
Enterprise Value | $1.06T | $19.70B |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →